Rosai-Dorfman Disease Overview

Save information for later
Sign Up

Learn About Rosai-Dorfman Disease

What is the definition of Rosai-Dorfman Disease?
Rosai-Dorfman disease is a benign disease which is characterized by over-production and accumulation of a specific type of white blood cell (histiocyte) in the lymph nodes of the body, most often those of the neck (cervical). Other lymph node groups may also be involved and, in some cases, abnormal accumulation of histiocytes may occur in other areas of the body (extranodal). The cause of this condition remains unknown, although altered immune responses and infectious agents may play a role.
What are the alternative names for Rosai-Dorfman Disease?
  • Rosai-Dorfman disease
  • RDD
  • Rosaï-Dorfman disease
  • SHML
  • Sinus histiocytosis with massive lymphadenopathy
Who are the top Rosai-Dorfman Disease Local Doctors?
Jithma P. Abeykoon
Elite in Rosai-Dorfman Disease
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology
Elite in Rosai-Dorfman Disease
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jithma Abeykoon is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Abeykoon is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Waldenstrom Macroglobulinemia, Reticulohistiocytoma, Histiocytosis, Tissue Biopsy, and Bone Marrow Transplant. Dr. Abeykoon is currently accepting new patients.

Elite in Rosai-Dorfman Disease
Dr. Gaurav Goyal
Hematology Oncology | Hematology | Oncology
Elite in Rosai-Dorfman Disease
Dr. Gaurav Goyal
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gaurav Goyal is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Goyal is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Goyal is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Rosai-Dorfman Disease
J J. Haroche
Elite in Rosai-Dorfman Disease
J J. Haroche
Paris, FR 

J Haroche practices in Paris, France. Haroche is rated as an Elite expert by MediFind in the treatment of Rosai-Dorfman Disease. Their top areas of expertise are Histiocytosis, Reticulohistiocytoma, Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, and Tissue Biopsy.

View All Doctors
What are the latest Rosai-Dorfman Disease Clinical Trials?
Efficacy and Safety of the RD Regimen (Lenalidomide, Dexamethasone) in the Treatment of Rosai-Dorfman Disease: A Prospective, Multicenter, Single-Arm Study.
Efficacy and Safety of the RD Regimen (Lenalidomide, Dexamethasone) in the Treatment of Rosai-Dorfman Disease: A Prospective, Multicenter, Single-Arm Study.
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.
A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.
Who is this study for: Patients with refractory Langerhans cell histiocytosis, LCH-associated neurodegenerative disease, and other histiocytic disorders
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Drug
Study Drug: Cobimetinib
Study Phase: Phase 2

Summary: This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center